Operating profit before amortization: ArriVent BioPharma Inc (AVBP)

Graphic logo of ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma, Inc (AVBP) is investing in costly clinical trials for an innovative inhibitor, which temporarily limits operating leverage. Absolute EBITDA visualizes this period, where the 0.00 metric determines this level. The business relies on external CMO plants, and future revenue is based on the procurement of targeted therapy by insurance companies for patients with rare mutations.

AVBP ArriVent BioPharma Inc Operating profit EBITDA (11/23/2025 - 11/12/2026)

ArriVent BioPharma Inc (AVBP) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price ArriVent BioPharma|AVBP - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization ArriVent BioPharma|AVBP - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share ArriVent BioPharma|AVBP - Book Capitalization|Market-to-Book Ratio arrivent.com|AVBP - Aggregate Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio ArriVent BioPharma, Inc|AVBP - Long-Term Debt to Capital|Short-Term Debt to Capital ArriVent|AVBP - Company Debts|Debt to Net Assets Ratio ArriVent BioPharma|AVBP - Company Long-Term Debt|Company Short-Term Loans and Borrowings ArriVent BioPharma|Interim Coverage Ratio arrivent.com
- earnings and multiples data:
AVBP - Net Income|Expected Profit ArriVent BioPharma, Inc|AVBP - P/E Multiple|Projected Price to Earnings Ratio arrivent.com|AVBP - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation ArriVent BioPharma|AVBP - Operating profit before deduction of amortization|Earnings per share for the last four quarters ArriVent BioPharma|AVBP - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months arrivent.com|AVBP - Earnings growth in current year|Net earnings per share growth forecast for next year ArriVent BioPharma, Inc
Analysis of all company metrics:ArriVent BioPharma, Inc
Brand item of ArriVent BioPharma Inc

ArriVent BioPharma, Inc (AVBP) minimizes capital expenditures by outsourcing clinical trials to third-party contractors. This model makes cash flow sensitive to the vendor payment schedule. This metric captures the daily volume of actual funds from commercial activities, excluding non-cash charges. It measures the actual liquidity of the operating cycle. Analyzing the company's operating result before depreciation and amortization allows for a distinction between temporary volatility and systemic business impairment.

Competitors of ArriVent BioPharma, Inc (AVBP)

Operating profit EBITDA Lantern Pharma Inc LTRN|BIAF - Profit before payment of interest, taxes and amortization|EFTR (effector.com) - Operating profit before amortization